Candel Therapeutics' CAN-2409 For Pancreatic Cancer Gets FDA Orphan Drug Designation; Stock Up

Candel Therapeutics, Inc. (CADL), Thursday announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to CAN-2409, for the treatment of pancreatic cancer.

Related Keywords

,Candel Therapeutics Inc ,Drug Administration ,Nasdaq ,Candel Therapeutics ,Orphan Drug Designation ,Fast Track Designation ,Orphan Drug Designation ,An 2409 ,An 2409 Plus Valacyclovir ,